- Home
- CEV vs BRNS Comparison
CEV vs BRNS Comparison
Compare CEV & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- BRNS
- Stock Information
- Founded
- CEV 1999
- BRNS 2016
- Country
- CEV United States
- BRNS United Kingdom
- Employees
- CEV N/A
- BRNS N/A
- Industry
- CEV Finance/Investors Services
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- BRNS Health Care
- Exchange
- CEV Nasdaq
- BRNS Nasdaq
- Market Cap
- CEV 70.8M
- BRNS 58.0M
- IPO Year
- CEV N/A
- BRNS 2021
- Fundamental
- Price
- CEV $10.10
- BRNS $1.61
- Analyst Decision
- CEV
- BRNS Strong Buy
- Analyst Count
- CEV 0
- BRNS 1
- Target Price
- CEV N/A
- BRNS $3.00
- AVG Volume (30 Days)
- CEV 19.6K
- BRNS 248.2K
- Earning Date
- CEV 01-01-0001
- BRNS 11-05-2025
- Dividend Yield
- CEV 4.23%
- BRNS N/A
- EPS Growth
- CEV N/A
- BRNS N/A
- EPS
- CEV 0.36
- BRNS N/A
- Revenue
- CEV N/A
- BRNS $14,969,000.00
- Revenue This Year
- CEV N/A
- BRNS N/A
- Revenue Next Year
- CEV N/A
- BRNS N/A
- P/E Ratio
- CEV $29.36
- BRNS N/A
- Revenue Growth
- CEV N/A
- BRNS 1766.46
- 52 Week Low
- CEV $8.83
- BRNS $0.64
- 52 Week High
- CEV $10.91
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- CEV 70.75
- BRNS 65.26
- Support Level
- CEV $10.04
- BRNS $1.36
- Resistance Level
- CEV $10.17
- BRNS $1.67
- Average True Range (ATR)
- CEV 0.08
- BRNS 0.17
- MACD
- CEV -0.01
- BRNS 0.05
- Stochastic Oscillator
- CEV 68.75
- BRNS 72.15
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.